Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized …

P Frohna, J Lu, S Eppler, M Hamilton… - The Journal of …, 2006 - Wiley Online Library
A randomized, open‐label, 2‐period crossover study was conducted to evaluate the
bioequivalence of 6 tablets of erlotinib 25 mg and 1 tablet of erlotinib 150 mg (arm A, n= 42) …
被引用次数：115 相关文章 所有 6 个版本
[PDF] psu.edu

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers

J Ling, KA Johnson, Z Miao, A Rakhit, MP Pantze… - Drug metabolism and …, 2006 - ASPET
Metabolism and excretion of erlotinib, an orally active inhibitor of epidermal growth factor
receptor tyrosine kinase, were studied in healthy male volunteers after a single oral dose of …
被引用次数：247 相关文章 所有 11 个版本
[PDF] academia.edu

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

ER Lepper, SM Swain, AR Tan, WD Figg… - … of Chromatography B, 2003 - Elsevier
A high-performance liquid-chromatographic (HPLC) assay with UV detection has been
developed for the quantitative determination of erlotinib (OSI-774) in human plasma …
被引用次数：64 相关文章 所有 11 个版本

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with …

N Yamamoto, A Horiike, Y Fujisaka… - Cancer chemotherapy …, 2008 - Springer
Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
被引用次数：90 相关文章 所有 13 个版本

A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
被引用次数：49 相关文章 所有 3 个版本

Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420

A Broniscer, JC Panetta, M O'Shaughnessy… - Clinical cancer …, 2007 - AACR
Purpose: To report cerebrospinal fluid (CSF) penetration of erlotinib and its metabolite OSI-
420. Experimental Design: Pharmacokinetic measurements were done in plasma (days 1, 2 …
被引用次数：119 相关文章 所有 6 个版本

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

J Ling, S Fettner, BL Lum, M Riek, A Rakhit - Anti-cancer drugs, 2008 - journals.lww.com
The effects of food on the pharmacokinetics of erlotinib were investigated in two open-label,
randomized studies. In a single-dose crossover study (n= 18), 150 mg of erlotinib was …
被引用次数：109 相关文章 所有 8 个版本

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human …

HJ Meany, E Fox, C McCully, C Tucker… - Cancer chemotherapy and …, 2008 - Springer
Purpose Erlotinib hydrochloride is a small molecule inhibitor of epidermal growth factor
receptor (EGFR). EGFR is over-expressed in primary brain tumors and solid tumors that …
被引用次数：45 相关文章 所有 11 个版本

Erlotinib hydrochloride.

JD Minna, J Dowell - Nature Reviews. Drug Discovery, 2005 - europepmc.org
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
被引用次数：48 相关文章 所有 2 个版本
[PDF] narod.ru

Erlotinib hydrochloride.

J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
被引用次数：238 相关文章 所有 14 个版本